Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

ClinicalTrials.gov ID: NCT03818256

Public ClinicalTrials.gov record NCT03818256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)

Study identification

NCT ID
NCT03818256
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Corcept Therapeutics
Industry
Enrollment
71 participants

Conditions and interventions

Interventions

  • Miricorilant Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2019
Primary completion
Jun 16, 2022
Completion
Jul 5, 2022
Last update posted
Sep 18, 2024

2019 – 2022

United States locations

U.S. sites
27
U.S. states
14
U.S. cities
26
Facility City State ZIP Site status
Site 143 Bentonville Arkansas 72712
Site 249 Little Rock Arkansas 72211
Site 153 Culver City California 90230
Site 239 Garden Grove California 92845
Site 134 Lemon Grove California 91945
Site 126 Oakland California 94607
Site 163 Oceanside California 92056
Site 229 Rancho Cucamonga California 91730
Site 202 Miami Florida 33122
Site 144 North Miami Florida 33161
Site 241 Okeechobee Florida 34972
Site 140 Chicago Illinois 60641
Site 140 Lincolnwood Illinois 60712
Site 146 Wichita Kansas 67214
Site 138 Glen Burnie Maryland 20161
Site 151 Las Vegas Nevada 89102
Site 216 New York New York 10032
Site 181 Raleigh North Carolina 27608
Site 181 Raleigh North Carolina 27610
Site 107 Dayton Ohio 45417
Site 235 Thorndale Pennsylvania 19372
Site 235 West Chester Pennsylvania 19380
Site 206 DeSoto Texas 75115
Site 066 Houston Texas 77030
Site 165 Richardson Texas 75080
Site 139 Salt Lake City Utah 84105
Site 137 Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03818256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03818256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →